参考文献/References:
[1] 周纯武,李二妮.乳腺影像学发展历程及展望[J].中华放射学杂志,2013,47增刊:27-29.
[2] 田荣华,王艳,汪娇,等.钼靶X线对乳腺癌的诊断(附174例分析)[J].实用放射学杂志,2011,27(11):1670-1672.
[3] 张洪涛,赵一冰,宋培记,等.钼靶乳腺摄像在乳腺癌新辅助化疗疗效评价中的应用[J].军事医学,2012,36(8):616-618.
[4] Sperber F,Weinstein Y,Sarid D,et al.Preoperative clinical,mammographic and sonographic assessment of neoadjuvant chemotherapy response in breast cancer[J].Isr Med Assoc J,2006,8(5):342-346.
[5] 夏晓天,张永学.影像学检查在乳腺癌的诊断及疗效评估中的应用价值[J].国际放射医学核医学杂志,2010,34(4):242-246,249.
[6] Belli P,Costantini M,Malaspina C,et al.MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy[J].Clin Radiol,2006,61(11):946-953.
[7] Choi JH,Lim HJ,Lee SK,et al.The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced,breast cancer:comparison with ultrasonography and magnetic resonance imaging[J].J Sur Oncol,2010,102(5):392-397.
[8] Wu LM,Hu JN,Gu HY,et al.Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?[J].Breast Cancer Res Treat,2012,135(1):17-28.
[9] 袁建伟,杨劼,贺小红,等.乳腺癌18F-FDG PET/CT和3.0T MRI联合显像评分与Ki-67表达水平的相关性分析[J].国际放射医学核医学杂志,2013,37(2):84-87.
[10] 郁骐襄,陈小松,沈坤炜.MRI在乳腺癌新辅助化疗中的地位[J].中华外科学杂志,2011,49(9):845-847.
[11] 李蔚萍,苗华栋,唐健雄,等.多排螺旋CT在乳腺癌诊断和术前中的价值[J].中华普通外科杂志,2011,26(1):29-32.
[12] 徐民,纪建松,卢陈英,等.多层螺旋CT对进展期乳腺癌新辅助化疗的疗效评估[J].医学影像学杂志,2012,22(10):1677-1680.
[13] Tozaki M,Kobayashi T,Uno S,et al.Breast-conserving surgery after chemotherapy:value of MDCT for determining tumor distribution and shrinkage pattern[J].AJR Am J Roentgenol,2006,186(2):431-439.
[14] 黄朝光,辛付莹,鲁毅.彩超、钼靶评价新辅助化疗疗效的应用研究[J].中外医疗,2011(17):181.
[15] Chen M,Zhan WW,Han BS,et al.Accuracy of physical examination,ultrasonography,and magnetic resonance imaging in predicting response to neo-adjuvant chemotherapy for breast cancer[J].Chin Med J(Engl),2012,120:1862-1866.
[16] Cao X,Xue J,Zhao B,et al.Potential application value of contrast-enhanced ultrasound in neoadjuvant chemotherapy of breast cancer[J].Ultrasound Med Biol,2012,38(12):2065-2071.
[17] 陈谦谦,薛恩生.超声、钼靶X线联合MRI在乳腺癌术前评价中的应用[J].中国医学影像学杂志,2012,20(2):148-152.
[18] Dietl B,Marienhagen J.The therapeutic impact of 18F-FDG whole body PET A radiooncologist’s view[J].Nuklearmedizin,2005,44(1):8-14.
[19] 席云,张敏,郭睿,等.18F-FDG PET或PET/CT评估乳腺癌新辅助化疗疗效价值的meta分析[J].中华核医学与分子影像杂志,2012,32(3):192-197.
[20] 贾丽,于金明,王仁本,等.18F-FDG PET/CT对乳腺癌新辅助化疗疗效预测的价值[J].中国肿瘤临床与康复,2006,13(3):215-218.
[21] Humbert O,Berriolo-Riedinger A,Riedinger JM,et al.Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer:influence of tumor subtypes[J],Ann Oncol,2012,23(10):2572-2577.
[22] Kumar A,Kumar R,Seenu V,et al.The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer[J].Eur Radiol,2009,19(6):1347-1357.
[23] Andrade WP,Lima EN,Osório CA,et al.Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?[J].EurJ Sur Onco,2013,39(12):1358-1363.
[24] Koolen BB,Valdés Olmos RA,Elkhuizen PH,et al.Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy[J].Breast Cancer ResTreat.2012,135(1):231-240.
[25] Koolen BB,Vranckhen Peeters MJ,Aukema TS,et al.18F-FDG PET/CT as a staging procedure in primary stage D and M breast cancer:comparison with conventional imaging techniques[J].Breast Cancer Res Treat,2012,131(1):117-126.
[26] 吴建伟,高红,艾书跃,等.PET/CT对乳腺癌术后转移的诊断意义[J].医学研究生学报,2013,26(1):41-44.
[27] Smyezek-Gargya B,Fersis N,Dittmann H,et al.PET with[18F] fluorothymidine for imaging of primary breast cancer:a pilot study[J],Eur J Nucl Med Mol Imaging,2004,31(5):720-724.
[28] van Waarde A,Cobben DC,Suurmeijer AJ,et al.Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model[J].J Nucl Med,2004,45(4):695-700.
[29] Yamamoto Y,Nishiyama Y,Ishikawa S,et al.3’-Deoxy-3’-18F-fluorothymidine as a proliteration imaging tracer for diagnosis of lung tumors:comparison with 2-deoxy-2-18f-fluoro-D-glucose[J].J Compute Assist Tomogr,2008,32(3):432-437.
[30] 陈雷,柳曦.18F-FDG和18F-FLT的正电子发射断层显像对肿瘤放化疗疗效评价的实验研究[J].中国医药导报,2013,10(18):41-43.
[31] Peterson LM,Mankoff DA,Lawton T,et al.Quantitative imagine of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol[J].J Nucl Med,2008,49(3):367-374.
[32] Dehdashti F,Flanagan FL,Mortimer JE,et al.Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy[J].Eur J Nucl Med,1999,26(1):51-56.
[33] Mortimer JE,Dehdashti F,Siegel BA,et al.Metabolic flare:indicator of hormone responsiveness in advanced breast cancer[J].J Clin Oncol,2001,19(11):2797-2803.
[34] Brepoels L,Stroobants S,Verhoef G,et al.18F-FDG and 18F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model[J].J Nucl Med,2009,50(7):1102-1109.
[35] Song SL,Liu JJ,Huang G,et al.Changes in 18F-FDG uptake within minutes after chemotherapy in a rabbit VX2 tumor model[J].J Nucl Med,2008,49(2):303-309.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[4]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[5]李海峰,张晓军,李云钢,等.国产模块LOOP环改良法合成11C-蛋氨酸[J].国际放射医学核医学杂志,2016,40(2):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
Li Haifeng,Zhang Xiaojun,Li Yungang,et al.Synthesis of 11C-methionine on home-made module by the improved LOOP method[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
[6]杨雷,袁卫红,王家平,等.99Tcm-MIBI显像与钼靶X线对乳腺癌诊断的比较研究[J].国际放射医学核医学杂志,2016,40(2):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
Yang Lei,Yuan Weihong,Wang Jiaping,et al.Diagnostic value of technetium 99Tcm sestamibi and X-ray mammography in breast cancer: a comparison study[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
[7]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[8]马乐,张万春,李晓敏.乳腺癌前哨淋巴结核素显像新进展[J].国际放射医学核医学杂志,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
Ma Le,Zhang Wanchun,Li Xiaomin.Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
[9]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[10]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[11]胡鸿,唐刚华,聂大红.乳腺癌分子显像研究进展[J].国际放射医学核医学杂志,2015,39(1):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
Hu Hong,Tang Ganghua,Nie Dahong.Progress on molecular imaging of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
[12]李雯,冯彦林.18F-FDG PET/CT评估三阴性乳腺癌新辅助化疗疗效的研究进展[J].国际放射医学核医学杂志,2014,38(3):197.[doi:10.3760/cma.j.issn.1673-4114.2014.03.013]
Li Wen,Feng Yanlin.Advances of assessment with 18F-FDG PET/CT in triple-negative breast cancer during neoadjuvant chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):197.[doi:10.3760/cma.j.issn.1673-4114.2014.03.013]
[13]胡梦裳,章斌.PET/CT显像在乳腺癌疗效评价及预后中的作用[J].国际放射医学核医学杂志,2014,38(5):332.[doi:10.3760/cma.j.issn.1673-4114.2014.05.013]
Hu Meng-shang,Zhang Bin.The role of PET/CT imaging in the evaluation of the efficacy and prognosis of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):332.[doi:10.3760/cma.j.issn.1673-4114.2014.05.013]
[14]袁建伟,杨劼,贺小红,等.乳腺癌18F-FDG PET/CT和3.0T MRI联合显像评分与Ki-67表达水平的相关性分析[J].国际放射医学核医学杂志,2013,37(2):84.[doi:10.3760/cma.j.issn.1673-4114.2013.02.006]
YUAN Jian-wei,YANG Jie,HE Xiao-hong,et al.Correlation between combined imaging modalities of 18F-FDG PET/CT and 3.0T MRI and expression of Ki-67 in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):84.[doi:10.3760/cma.j.issn.1673-4114.2013.02.006]
[15]袁建伟,杨劼,贺小红,等.18F-FDG PET/CT与3.0T MRI联合显像在乳腺癌原发病灶诊断中的价值[J].国际放射医学核医学杂志,2013,37(4):199.[doi:10.3760/cma.j.issn.1673-4114.2013.04.003]
YUAN Jian-wei,YANG Jie,HE Xiao-hong,et al.Diagnosis value of 18F-FDG PET/CT and 3.0T MRI combined imaging in detecting the primary focus of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):199.[doi:10.3760/cma.j.issn.1673-4114.2013.04.003]
[16]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[17]夏晓天,张永学.影像学检查在乳腺癌的诊断及疗效评估中的应用价值[J].国际放射医学核医学杂志,2010,34(4):242.[doi:10.3760/cma.j.issn.1673-4114.2010.04.014]
XIA Xiao-tian,ZHANG Yong-xue.The value of imaging examinations in diagnosis and curative effect evaluation of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(6):242.[doi:10.3760/cma.j.issn.1673-4114.2010.04.014]
[18]鲁胜男,冯彦林.乳腺癌新辅助化疗过程中18F-FDG PET-CT与化疗前Ki-67、COX-2表达的相关性研究[J].国际放射医学核医学杂志,2011,35(4):238.[doi:10.3760/cma.j.issn.1673-4114.2011.04.011]
LU Sheng-nan,FENG Yan-lin.The correlation analysis between 18F-FDG PET-CT in breast cancer with neoadjuvant chemotherapy and the expression of Ki-67 and COX-2 before neoadjuvant chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):238.[doi:10.3760/cma.j.issn.1673-4114.2011.04.011]
[19]张亶,章斌,邓胜明,等.18F-FDG PET/CT在乳腺癌术后随访中的价值[J].国际放射医学核医学杂志,2017,41(3):159.[doi:10.3760/cma.j.issn.1673-4114.2017.03.001]
Zhang Dan,Zhang Bin,Deng Shengming,et al.Clinical value of 18F-FDG PET/CT in follow-up of postoperative breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(6):159.[doi:10.3760/cma.j.issn.1673-4114.2017.03.001]